Affiliation:
1. Integrated Medicines Ltd, Topfield House, Ermine Street, Caxton, Cambridge, CB23 3PQ, UK.
Abstract
Acceptance and operation of a personalized medicine strategy within modern healthcare requires that all key stakeholders are able to understand and assess the benefits offered by the approach. In addition to the technological aspects of molecular diagnostics, as enablers of personalized medicine, stakeholders must also be apprised of the value-adding effects of the strategy in terms of improved treatment efficacy and health economics. This review attempts to cover these broad stakeholder interests by articulating the scientific feasibility, the beneficial medical outcomes and the commercial attractiveness offered by the integration of molecular diagnostics and personalized medicine into healthcare systems, principally by demonstrating how technology integration and value addition can be robustly assessed and represented.
Subject
Pharmacology,Molecular Medicine,General Medicine
Reference49 articles.
1. Clinical application of pharmacogenetics
2. ChristensenCM, Grossman JH, Hwang J:The Innovator’s Prescription: A Disruptive Solution for Health Care.McGraw-Hill, NY, USA (2009).
3. The microeconomics of personalized medicine: today's challenge and tomorrow's promise
4. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
5. BrownG:The Living End: The Future of Death, Aging and Immortality. Palgrave MacMillan, Hampshire, UK (2008).
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献